Pharmacogenomic Characterization in Bipolar Spectrum Disorders

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2019 Dec 28

PMID 31877761

Citations 6

Authors

Stefano Fortinguerra

Vincenzo Sorrenti

Pietro Giusti

Morena Zusso

Alessandro Buriani

Affiliations

Soon will be listed here.

Abstract

The holistic approach of personalized medicine, merging clinical and molecular characteristics to tailor the diagnostic and therapeutic path to each individual, is steadily spreading in clinical practice. Psychiatric disorders represent one of the most difficult diagnostic challenges, given their frequent mixed nature and intrinsic variability, as in bipolar disorders and depression. Patients misdiagnosed as depressed are often initially prescribed serotonergic antidepressants, a treatment that can exacerbate a previously unrecognized bipolar condition. Thanks to the use of the patient's genomic profile, it is possible to recognize such risk and at the same time characterize specific genetic assets specifically associated with bipolar spectrum disorder, as well as with the individual response to the various therapeutic options. This provides the basis for molecular diagnosis and the definition of pharmacogenomic profiles, thus guiding therapeutic choices and allowing a safer and more effective use of psychotropic drugs. Here, we report the pharmacogenomics state of the art in bipolar disorders and suggest an algorithm for therapeutic regimen choice.

Citing Articles

Mood disorders and 5-HTR2A genetic variants - the moderator effect of inflammation on expression of affective polarity phenotype.

Pantovic-Stefanovic M, Karanovic J, Jurisic V, Dunjic-Kostic B, Nesic M, Dodic S BMC Psychiatry. 2024; 24(1):747.

PMID: 39472813 PMC: 11520582. DOI: 10.1186/s12888-024-06207-y.

Effect of antipsychotics and mood stabilisers on metabolism in bipolar disorder: a network meta-analysis of randomised-controlled trials.

Kong L, Wang H, Yan N, Xu C, Chen Y, Zeng Y EClinicalMedicine. 2024; 71:102581.

PMID: 38618207 PMC: 11015341. DOI: 10.1016/j.eclinm.2024.102581.

A Longitudinal Study of the Association between the Polymorphism and Treatment Response in Patients with Bipolar Disorder.

Chang H, Hsueh Y, Cheng Y, Tseng H Int J Mol Sci. 2022; 23(17).

PMID: 36077028 PMC: 9455965. DOI: 10.3390/ijms23179635.

Gut Microbiota - A Potential Contributor in the Pathogenesis of Bipolar Disorder.

Zhang P, Kong L, Huang H, Pan Y, Zhang D, Jiang J Front Neurosci. 2022; 16:830748.

PMID: 35401095 PMC: 8984199. DOI: 10.3389/fnins.2022.830748.

Genetic Variations Associated with Long-Term Treatment Response in Bipolar Depression.

Anmella G, Vilches S, Espadaler-Mazo J, Murru A, Pacchiarotti I, Tuson M Genes (Basel). 2021; 12(8).

PMID: 34440433 PMC: 8391230. DOI: 10.3390/genes12081259.

References

Fortinguerra S, Buriani A, Sorrenti V, Lenzi M, Giusti P . Molecular network-selected pharmacogenomics in a case of bipolar spectrum disorder. Pharmacogenomics. 2017; 18(18):1631-1642. DOI: 10.2217/pgs-2017-0133. View

Ghaemi S, Hsu D, Soldani F, Goodwin F . Antidepressants in bipolar disorder: the case for caution. Bipolar Disord. 2003; 5(6):421-33. DOI: 10.1046/j.1399-5618.2003.00074.x. View

Edvardsen J, Torgersen S, Roysamb E, Lygren S, Skre I, Onstad S . Heritability of bipolar spectrum disorders. Unity or heterogeneity?. J Affect Disord. 2007; 106(3):229-40. DOI: 10.1016/j.jad.2007.07.001. View

Zhang J, Robinson D, Gallego J, John M, Yu J, Addington J . Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis. Schizophr Bull. 2015; 41(6):1248-55. PMC: 4601717. DOI: 10.1093/schbul/sbv116. View

Li H, Wang X, Zhou Y, Ni G, Su Q, Chen Z . Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid. Int J Neuropsychopharmacol. 2015; 18(7):pyv021. PMC: 4540110. DOI: 10.1093/ijnp/pyv021. View

Balan S, Sathyan S, Radha S, Joseph V, Radhakrishnan K, Banerjee M . GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures. Pharmacogenet Genomics. 2013; 23(11):605-10. DOI: 10.1097/FPC.0000000000000000. View

Grasmader K, Verwohlt P, Rietschel M, Dragicevic A, Muller M, Hiemke C . Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 2004; 60(5):329-36. DOI: 10.1007/s00228-004-0766-8. View

Liu B, Zhang J, Wang L, Li X, Wang Y, Wei Z . HTR2C promoter polymorphisms are associated with risperidone efficacy in Chinese female patients. Pharmacogenomics. 2010; 11(5):685-92. DOI: 10.2217/pgs.10.23. View

Chen Z, Liew D, Kwan P . Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment. Neurology. 2016; 86(12):1086-94. DOI: 10.1212/WNL.0000000000002484. View

10.

Keers R, Bonvicini C, Scassellati C, Uher R, Placentino A, Giovannini C . Variation in GNB3 predicts response and adverse reactions to antidepressants. J Psychopharmacol. 2010; 25(7):867-74. DOI: 10.1177/0269881110376683. View

11.

Chung J, Cho J, Yu K, Kim J, Lim K, Sohn D . Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2007; 83(4):595-600. DOI: 10.1038/sj.clpt.6100324. View

12.

Risselada A, Vehof J, Bruggeman R, Wilffert B, Cohen D, Al Hadithy A . Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics J. 2010; 12(1):62-7. DOI: 10.1038/tpj.2010.66. View

13.

Barnett J, Smoller J . The genetics of bipolar disorder. Neuroscience. 2009; 164(1):331-43. PMC: 3637882. DOI: 10.1016/j.neuroscience.2009.03.080. View

14.

Xiong Y, Wei Z, Huo R, Wu X, Shen L, Li Y . A pharmacogenetic study of risperidone on chemokine (C-C motif) ligand 2 (CCL2) in Chinese Han schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2014; 51:153-8. DOI: 10.1016/j.pnpbp.2014.01.017. View

15.

Jun C, Choi Y, Lim S, Bae S, Hong Y, Kim J . Disturbance of the glutamatergic system in mood disorders. Exp Neurobiol. 2014; 23(1):28-35. PMC: 3984954. DOI: 10.5607/en.2014.23.1.28. View

16.

Amare A, Schubert K, Hou L, Clark S, Papiol S, Heilbronner U . Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study. JAMA Psychiatry. 2017; 75(1):65-74. PMC: 5833535. DOI: 10.1001/jamapsychiatry.2017.3433. View

17.

Ghaemi S, Sachs G, Chiou A, Pandurangi A, Goodwin K . Is bipolar disorder still underdiagnosed? Are antidepressants overutilized?. J Affect Disord. 1999; 52(1-3):135-44. DOI: 10.1016/s0165-0327(98)00076-7. View

18.

Li L, Hu F, Wu X, An D, Yan B, Zhou D . Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese. Epilepsy Res. 2013; 106(1-2):296-300. DOI: 10.1016/j.eplepsyres.2013.05.004. View

19.

Yatham L, Kennedy S, Parikh S, Schaffer A, Bond D, Frey B . Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018; 20(2):97-170. PMC: 5947163. DOI: 10.1111/bdi.12609. View

20.

Serretti A, Calati R, Mandelli L, De Ronchi D . Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets. 2006; 7(12):1659-69. DOI: 10.2174/138945006779025419. View